Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

FDA approves expanded indication for Gilotrif

FDA approves expanded indication for Gilotrif It showed Gilotrif achieved its primary objective of significantly improving progression-free survival when compared against Roche/Astellas' Tarceva (erlotinib).

FDA panel says no to quick approval of Clovis' rociletinib

FDA panel says no to quick approval of Clovis' rociletinib The drug is a third-generation EGFR inhibitor designed for use when other drugs in the class - Roche/Astellas' market-leading Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer Ingelheim's

Boehringer's Giotrif wins new NSCLC licence in Europe

Boehringer's Giotrif wins new NSCLC licence in Europe Giotrif reached its primary endpoint in the study of significantly delaying the progression of SqCC of the lung when compared against Roche/Astellas' Tarceva (erlotinib). ... year. Giotrif joins several EGFR-targeting therapies on the market, including

Japanese approvals for GSK, AZ and Bayer

Japanese approvals for GSK, AZ and Bayer The drug has been cleared for use in patients who have developed resistance to other EGFR inhibitors such as Roche/Astellas' Tarceva (erlotinib), AZ's Iressa (gefitinib) and Boehringer Ingelheim's

AstraZeneca wins European approval for Tagrisso

AstraZeneca wins European approval for Tagrisso Almost two thirds of patients treated with older treatments such as AstraZeneca's Iressa (gefitinib), Boehringer Ingelheim's Giotrif (afatinib) or Roche/Astellas' Tarceva (erlotinib) develop the T790M mutation and face

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics